Brain

Quibim Announces New Board of Directors To Promote Growth And Strategic Expansion

NEW YORK & VALENCIA, Spain & CAMBRIDGE, England--(BUSINESS WIRE)--#AIinHealthcare--Quibim, the global pioneer in imaging biomarkers for precision medicine, is pleased…

10 months ago

CAS and Cleveland Clinic collaborate to accelerate research through advanced AI and quantum computing

COLUMBUS, Ohio, April 7, 2025 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific content and…

10 months ago

2025 ZGC Forum: Gala for Global Sci-tech Cooperation

BEIJING, April 7, 2025 /PRNewswire/ -- A report from Science and Technology Daily: The 2025 Zhongguancun Forum Annual Conference (2025 ZGC…

10 months ago

Cala Presents Multiple Clinical Studies Demonstrating Impact of Transcutaneous Afferent Patterned Stimulation (TAPS) Therapy in Essential Tremor (ET) Patients at the American Academy of Neurology (AAN)

SAN MATEO, Calif., April 7, 2025 /PRNewswire/ -- Cala, the bioelectronic medicine leader, who recently raised an oversubscribed growth financing round…

10 months ago

Make Time Wellness Announces Launch of Award-Winning Products at The Vitamin Shoppe

New Wellness Solutions Available Starting April 2025, Empowering Women to Prioritize Their Brain Health LOS ANGELES, April 7, 2025 /PRNewswire/…

10 months ago

UK Pilot launched to detect early signs of dementia & improve brain health

The Pilot Program uses a unique "Human + AI" (HAI) model to interact with patients & monitor progress. LONDON, April…

10 months ago

European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in…

10 months ago

Lenire Supports Veterans by Sponsoring Hearoes Tour

Lenire proudly sponsors the 10th Annual LexCare Hearing Foundation Hearoes Tour.Lenire is a treatment option for 3.2m veterans living with…

10 months ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine…

10 months ago